×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Actinic Keratosis Treatment Market

ID: MRFR/Pharma/1746-CR
95 Pages
Rahul Gotadki
July 2019

Actinic Keratosis Treatment Market Research Report Information By Type (Medications and Procedures), By End User (Hospitals & Oncology Centers, Dermatology Clinics and Ambulatory Surgical Center) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Actinic Keratosis Treatment Market Infographic
Purchase Options

Actinic Keratosis Treatment Market Summary

As per Market Research Future Analysis, the Actinic Keratosis Treatment Market is projected to reach USD 4.78 Billion by 2035, growing at a CAGR of 13.39% from 2023 to 2035. The market is driven by the rising incidence of actinic keratosis, increased adoption of minimally invasive treatments, and favorable medical reimbursement policies. However, high treatment costs and complications remain significant barriers to growth. The market is segmented by type, medication, procedure, and end-user, with cryotherapy and diclofenac gel expected to lead in their respective categories. North America is anticipated to dominate the market due to advanced treatment availability and a high prevalence of actinic keratosis, while Asia-Pacific is expected to be the fastest-growing region due to an increasing geriatric population and medical tourism opportunities.

Key Market Trends & Highlights

Key trends influencing the Actinic Keratosis Treatment Market include:

  • Market Size: USD 4.78 Billion by 2035; CAGR: 13.39% (2023-2035)
  • North America held over 40% market share in 2017; expected to remain dominant
  • Cryotherapy expected to have the largest market share in procedures
  • Diclofenac gel projected to rise faster than other medications by 2024

Market Size & Forecast

Market Size USD 4.78 Billion by 2035
CAGR 13.39% (2024-2035)
Largest Regional Market Share in 2024 North America

Major Players

Stanford Chemicals (US), Alma Lasers (Israel), 3M (US), Sun Pharmaceutical Industries Ltd. (India), Galderma S.A (Switzerland), Leo Pharma (Denmark), Valeant Pharmaceuticals (US), BioLineRx (Israel), Cipher Pharmaceuticals Inc (Canada), Biofrontera AG (Germany)

Actinic Keratosis Treatment Market Drivers

Market Growth Projections

The Global Actinic Keratosis Treatment Market Industry is poised for substantial growth, with projections indicating a market value of 1.2 USD Billion in 2024 and an anticipated increase to 4.78 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate of 13.39% from 2025 to 2035. Such figures underscore the increasing recognition of actinic keratosis as a significant public health concern, driving investments in research, treatment development, and patient education initiatives. As the market evolves, stakeholders are likely to focus on enhancing treatment accessibility and effectiveness.

Growing Geriatric Population

The global demographic shift towards an aging population is a significant factor influencing the Global Actinic Keratosis Treatment Market Industry. Older adults are more susceptible to skin conditions, including actinic keratosis, due to cumulative sun exposure over their lifetimes. As the proportion of elderly individuals increases, so does the demand for effective treatment options. This demographic trend is particularly pronounced in developed nations, where healthcare systems are adapting to meet the needs of older patients. Consequently, the market is likely to expand, driven by the necessity for targeted therapies that address the unique challenges faced by this population.

Regulatory Support and Approval

Regulatory bodies are playing a crucial role in shaping the Global Actinic Keratosis Treatment Market Industry by facilitating the approval of new therapies. Streamlined processes for clinical trials and drug approvals are encouraging pharmaceutical companies to invest in research and development for actinic keratosis treatments. This supportive regulatory environment not only accelerates the introduction of innovative therapies but also enhances market competition. As more treatment options become available, patients benefit from increased choice and improved outcomes, further stimulating market growth.

Increased Awareness and Education

Heightened awareness about actinic keratosis and its potential risks is driving growth in the Global Actinic Keratosis Treatment Market Industry. Educational campaigns by health organizations and dermatology associations are informing the public about the importance of early detection and treatment. This increased knowledge encourages individuals to seek medical advice and treatment options, leading to higher diagnosis rates. Furthermore, healthcare providers are becoming more vigilant in screening for actinic keratosis, contributing to a larger patient base. As a result, the market is expected to experience a compound annual growth rate of 13.39% from 2025 to 2035.

Advancements in Treatment Modalities

Innovations in treatment options for actinic keratosis are shaping the Global Actinic Keratosis Treatment Market Industry. New therapies, including topical medications, cryotherapy, and photodynamic therapy, are being developed and refined, offering patients more effective and less invasive choices. For instance, the introduction of novel topical agents has shown promising results in clinical trials, enhancing patient compliance and satisfaction. As these advancements continue to emerge, they are likely to attract more patients seeking treatment, thereby expanding the market. The anticipated growth trajectory suggests that the market could reach 4.78 USD Billion by 2035.

Rising Incidence of Actinic Keratosis

The increasing prevalence of actinic keratosis globally is a primary driver for the Global Actinic Keratosis Treatment Market Industry. Factors such as prolonged sun exposure and aging populations contribute to this rise. It is estimated that millions of individuals are affected by this condition, particularly in regions with high UV radiation. As awareness grows regarding the potential progression of actinic keratosis to skin cancer, there is a corresponding surge in demand for effective treatments. This trend is expected to propel the market significantly, with projections indicating a market value of 1.2 USD Billion in 2024.

Market Segment Insights

Actinic Keratosis Treatment Market Procedure Insights

Based on the procedure, the actinic keratosis market is divided into cryotherapy, photodynamic therapy, laser, chemical peel, and others. Among these, the cryosurgery segment had the largest market share in 2017 and is expected to have a high CAGR during the forecast period. Cryotherapy is a widely used medication for actinic keratosis, although creating successful photodynamic therapy is expected to remain a primary focus for major players in the market for actinic keratosis in the coming years.

Actinic Keratosis Treatment Market Medication Insights

By medication, the Actinic Keratosis Treatment Market is segmented into imiquimod cream, fluorouracil cream, Ingenol mebutate gel, and diclofenac gel. The diclofenac gel segment is expected to have risen comparatively faster than in 2024.

Actinic Keratosis Treatment Market Type Insights

The Actinic Keratosis Treatment Market is segmented into drugs and procedures on the basis of the type. In 2017, the procedural division held the largest market share and is likely to outperform the former over the evaluation period. This is partly due to the performance, quick outcomes and ease of use of procedures.

Actinic Keratosis Treatment Market End User Insights

On the basis of end-users, the industry is segmented into hospitals & oncology centres, dermatology clinics, outpatient surgery centres, and others. The hospital and oncology centre market is projected to remain extremely lucrative in 2018 and beyond, as hospitals and oncology centres have a high incidence of patients. Hospitals and oncology centres are expected to hold a commanding actinic keratosis market share in the global market for actinic keratosis over the projected period, with dermatology diagnostic clinics emerging as another leading segment of the Actinic Keratosis Treatment Market.

Get more detailed insights about Actinic Keratosis Treatment Market

Key Companies in the Actinic Keratosis Treatment Market market include

Industry Developments

  • Q2 2024: Almirall receives FDA approval for Klisyri (tirbanibulin) for the treatment of actinic keratosis on the face or scalp Almirall announced that the U.S. FDA has approved Klisyri (tirbanibulin) ointment for the topical treatment of actinic keratosis on the face or scalp, marking a significant regulatory milestone for the company in the dermatology sector.
  • Q1 2024: LEO Pharma launches Adtralza (tralokinumab) in new markets for actinic keratosis treatment LEO Pharma expanded the availability of Adtralza (tralokinumab), introducing the product in several new European countries for the treatment of actinic keratosis, strengthening its dermatology portfolio.
  • Q2 2024: Biofrontera AG receives marketing authorization for Ameluz in Brazil for actinic keratosis Biofrontera AG announced that its photodynamic therapy product Ameluz has received marketing authorization in Brazil for the treatment of actinic keratosis, expanding its international footprint.
  • Q2 2024: Cipher Pharmaceuticals announces partnership with Sun Pharmaceutical for distribution of actinic keratosis treatment in Canada Cipher Pharmaceuticals entered into a strategic partnership with Sun Pharmaceutical to distribute its actinic keratosis treatment products in the Canadian market.
  • Q3 2024: Galderma launches new clinical trial for investigational topical therapy for actinic keratosis Galderma initiated a Phase III clinical trial to evaluate the safety and efficacy of a new investigational topical therapy for actinic keratosis, aiming to expand its treatment options.
  • Q1 2025: Hill Dermaceuticals receives FDA orphan drug designation for novel actinic keratosis treatment Hill Dermaceuticals announced that the FDA has granted orphan drug designation to its investigational therapy for actinic keratosis, providing regulatory incentives for further development.
  • Q2 2025: Bausch Health launches new manufacturing facility for actinic keratosis topical treatments in the United States Bausch Health Companies Inc. opened a new manufacturing facility dedicated to producing topical treatments for actinic keratosis, increasing its production capacity to meet rising demand.
  • Q2 2024: LEO Pharma announces acquisition of Vidac Pharmaceuticals to expand actinic keratosis portfolio LEO Pharma acquired Vidac Pharmaceuticals, aiming to strengthen its portfolio of actinic keratosis treatments and accelerate innovation in dermatology.
  • Q3 2024: Athenex, Inc. secures $30 million Series B funding to advance actinic keratosis drug development Athenex, Inc. raised $30 million in Series B funding to support the clinical development of its novel actinic keratosis drug candidates.
  • Q1 2025: GALDERMA receives EMA approval for new actinic keratosis gel formulation GALDERMA announced that the European Medicines Agency (EMA) has approved its new gel formulation for the treatment of actinic keratosis, enabling commercialization across the EU.
  • Q2 2025: Sun Pharmaceutical launches generic imiquimod cream for actinic keratosis in India Sun Pharmaceutical Industries Ltd. launched a generic version of imiquimod cream for the treatment of actinic keratosis in India, expanding access to affordable therapies.
  • Q2 2024: Perrigo Company plc appoints new CEO to drive growth in dermatology and actinic keratosis segment Perrigo Company plc announced the appointment of a new CEO, with a strategic focus on expanding its dermatology business, including actinic keratosis treatments.

Future Outlook

Actinic Keratosis Treatment Market Future Outlook

The Actinic Keratosis Treatment Market is poised for growth at 13.39% CAGR from 2024 to 2035, driven by increasing skin cancer awareness and innovative treatment options.

New opportunities lie in:

  • Develop targeted therapies utilizing advanced biotechnology for personalized treatment. Expand telemedicine platforms for remote consultations and follow-ups in dermatology. Invest in educational campaigns to raise awareness about actinic keratosis prevention and treatment.

By 2035, the market is expected to achieve substantial growth, reflecting enhanced treatment accessibility and innovation.

Market Segmentation

Actinic Keratosis Treatment Market Segmentation

  • Actinic Keratosis Treatment Market Type
  • Medications
  • Procedures
  • Actinic Keratosis Treatment Market End-User
  • Hospitals & Oncology Centers
  • Dermatology Clinics
  • Ambulatory Surgical Center
  • Actinic Keratosis Treatment Market Medication
  • fluorouracil cream
  • imiquimod cream
  • Ingenol mebutate gel
  • diclofenac gel
  • Actinic Keratosis Treatment Market Based on Procedure
  • crytherapy
  • photodynamic therapy
  • laser
  • chemical peel
  • others

Report Scope

Attribute/MetricDetails
  Market Size 2035  USD 4.78 Billion
  CAGR  13.39% (2024 - 2035) 
  Base Year2023
  Forecast Period  2023-2035
  Historical Data  2021
  Forecast Units  Value (USD Billion)
  Report Coverage  Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered  Type, Medication, Procedure, and End User
  Geographies Covered  North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors  Stanford Chemicals (US), Alma Lasers (Israel), 3M (US), Sun Pharmaceutical Industries Ltd. (India), Galderma S.A (Switzerland), Leo Pharma (Denmark), Valeant Pharmaceuticals (US), BioLineRx (Israel), Cipher Pharmaceuticals Inc (Canada), Biofrontera AG (Germany
  Key Market Opportunities  Growing Markets in Asia-Pacific
  Key Market DriversIncreasing Prevalence Of Actinic Keratosis Rising Demand And Acceptance Of Minimally Invasive Therapeutic Procedures Suitable Medical Coverage For A Variety Of Treatment Options Available In The Market Growing Geriatric Population Drivers Impact Analysis

Market Highlights

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Leave a Comment

FAQs

What will be the CAGR value of actinic keratosis treatment market during the forecast period ?

The actinic keratosis treatment market CAGR would be 13.39% during the forecast period.

What is the projected valuation for the Actinic Keratosis Treatment Market by 2035?

The valuation would be USD 4.78 Billion by 2035.

What are the restraining factors of the Actinic Keratosis Treatment Market?

The restraining factors of the market are high cost and various associated risks.

What was the hospital & oncology centers segment valuation in 2035?

The valuation was USD 4.78 Billion in 2035.

Which region would dominate the global Actinic Keratosis Treatment Market?

The Americas would dominate the Actinic Keratosis Treatment Market.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions